CDNA vs PFE: fair value comparison
CareDx, Inc. and Pfizer Inc. · Updated 2026-09-12
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. CDNA carries the stronger quality grade.
| CDNA | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $48.97 | $27.72 |
| 12-month range | $14.77–$48.97 | $24.23–$28.55 |
| Sector rank | #107 of 113 Healthcare | #103 of 113 Healthcare |
| Quality grade | A | D |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CDNA fair value analysis · PFE fair value analysis